US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
In a recent filing, CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH) reported that its CEO, Ryan Khouri, acquired a significant number of shares. On June 9, 2025, Khouri purchased 82,158 shares of the company at $0.05 per share, totaling $4,107. This transaction increased his direct ownership to 6,832,558 shares. The purchase price represents a premium to the current trading price of $0.03, with the stock trading near its 52-week low of $0.02 and significantly below its high of $0.15.
Additionally, on April 11, 2025, Khouri acquired 150,000 shares at $0.06 per share, amounting to $9,000. These acquisitions reflect Khouri’s continued investment in the company, aligning his interests with those of the shareholders. With a market capitalization of just $1.49 million and a weak financial health score, InvestingPro analysis reveals 11 additional key insights about CTTH’s investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.